Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, California.
Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, California.
Am J Cardiol. 2023 Oct 1;204:14-21. doi: 10.1016/j.amjcard.2023.07.087. Epub 2023 Aug 1.
Patients with repaired tetralogy of Fallot are at elevated risk for ventricular arrhythmia and sudden cardiac death. Over the past decade, the pathogenesis and natural history of ventricular tachycardia has become increasingly understood, and catheter ablation has emerged as an effective treatment modality. Concurrently, there has been great progress in the development of a versatile array of transcatheter valves that can be placed in the native right ventricular outflow tract for the treatment of long-standing pulmonary regurgitation. Although such valve platforms may eliminate the need for repeat cardiac operations, they may also impede catheter access to the myocardial substrates responsible for sustained macro-reentrant ventricular tachycardia. This manuscript provides the rationale and design of a recently devised multicenter study that will examine the clinical outcomes of a uniform, preemptive strategy to eliminate ventricular tachycardia substrates before transcatheter pulmonary valve implantation in patients with tetralogy of Fallot.
修复后的法洛四联症患者发生室性心律失常和心源性猝死的风险增加。在过去的十年中,室性心动过速的发病机制和自然史越来越被人们所理解,导管消融已成为一种有效的治疗方式。同时,在开发多种可用于治疗长期肺动脉瓣反流的经导管瓣膜方面也取得了巨大进展,这些瓣膜可置于原生右心室流出道。尽管此类瓣膜平台可能无需再次进行心脏手术,但也可能阻碍导管到达负责持续性大折返性室性心动过速的心肌基质。本文提供了最近设计的多中心研究的基本原理和设计方案,该研究将检查在法洛四联症患者接受经导管肺动脉瓣植入术前消除室性心动过速基质的统一、预防性策略的临床结果。